Solid Tumors Clinical Trial
Official title:
Clinical Study Protocol RTA 402-C-0501: A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDO-Me) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Verified date | July 2012 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Primary:
- To determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase
II dose of RTA 402 capsules in patients with advanced solid tumors or lymphoid
malignancies who have failed standard-of-care curative or survival-prolonging therapy,
or for whom no such therapies exist.
- To characterize the pharmacokinetics of RTA 402 capsules administered orally for 21
days in this patient population.
Secondary:
- To document any preliminary antitumor activity of RTA 402 in this patient population.
- To determine the in vivo molecular and biological effects of RTA 402 by measuring
changes in markers of differentiation, apoptosis, and anti-inflammatory effects in
WBCs, blood plasma, and, in consenting patients, tumor biopsies.
- To correlate the biological activity of RTA 402 with drug concentration in plasma and
blood cellular elements
- To evaluate the series of inflammation related symptoms over the course of the study,
and to determine the correlation of symptom intensity with plasma cytokines.
Status | Completed |
Enrollment | 21 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion: 1. Age >/= 18 years 2. Patient must have histopathological documentation of solid tumor or lymphoid malignancy. (measurable disease is not required) 3. Patient must have advanced or metastatic cancer that are either refractory or has relapsed after standard-of-care curative or survival-prolonging therapy, or for whom no such therapies exist. (there is no limit on the number of prior lines of therapy) 4. Patient must be ECOG performance status of less than or equal to 2. 5. Patient must have adequate liver and renal function as documented by the following laboratory test results within 14 days of starting therapy: - total bilirubin </= 1.5 mg/dL - AST (SGOT) and ALT(SGPT) </= 2.5 ULN or - </= 5 ULN if liver is involved by tumor - creatinine </= 2.0 mg/dL OR creatinine clearance > 60 mL/min 6. Patient must have adequate bone marrow function as documented by the following laboratory test results within 14 days of starting therapy: - platelets greater than 100,000/mm^3, - absolute granulocyte count greater than 1,500/mm^3, - hemoglobin greater than or equal to 8.0 g/dl. 7. Patient must have completed prior chemotherapy, hormonal therapy, radiation therapy, biological therapy, or other investigational cancer therapy at least 4 weeks prior to starting RTA 402, and must have recovered from all acute side effects (to CTC grade 1 or less) prior to initiation of RTA 402. Patients who were receiving mitomycin C or nitrosoureas must be 6 weeks from the last administration of chemotherapy. 8. Patient (man or woman) must agree to practice effective contraception during the entire study period unless documentation of infertility exists. 9. Patient must have a life expectancy of more than 3 months. 10. Patient must be able and willing to sign the informed consent form. 11. Patient must be willing and able to self-administer orally and document all doses of RTA 402 ingested. Exclusion: 1. Patients with active brain metastases or primary CNS malignancies. (patients with a previously treated brain metastasis may be included) 2. Patients who are pregnant or breast feeding 3. Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to: - uncontrolled diabetes - active or uncontrolled infection - acute or chronic liver disease (i.e., hepatitis, cirrhosis) - confirmed diagnosis of HIV infection - uncontrolled hypertension, symptomatic congestive heart failure, - unstable angina pectoris, - myocardial infarction within the past 6 months, or - uncontrolled cardiac arrhythmia. 4. Patients with psychiatric illness that would limit compliance with study requirements |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | UT MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | Reata Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose of RTA 402 | 28 day cycles | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |